UroGen Pharma Ltd.URGN stock score: 58/100
$31.73 · +6.51% · Scored Nov 19, 2026
- Technical
- 54
- Fundamental
- 58
- News
- 53
The reading
UroGen Pharma (URGN) scores 58 out of 100, which reads neutral, higher than 69% of Healthcare stocks and 69% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 58, technicals 54.
Among the fundamentals, Price Target at 100 and Revenue Growth (Quarterly) at 100 score highest, while Earnings Quality (Annual) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 48 and contrarian oscillators 48.
News sentiment is neutral at 53; it is shown, not counted in the composite.
Since Aug 22, 2026 the composite has ranged from 44 to 58, and it is up 1 point over the period.
About UroGen Pharma
UroGen Pharma (URGN) is a biotechnology company focused on treatments for urothelial and other specialty cancers. Its products use a proprietary reverse-thermal hydrogel that is liquid when cold and turns into a gel at body temperature, letting the chemotherapy drug mitomycin stay in contact with tumors longer than a standard liquid would. JELMYTO treats low-grade upper tract urothelial cancer, which forms in the lining of the kidney and ureter. ZUSDURI treats recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer, giving patients an option that can avoid repeated surgery to remove tumors. The company is developing UGN-103, a next-generation version for bladder cancer, along with other pipeline programs. Urologists administer the products in clinics and hospitals, and UroGen earns money from product sales to specialty distributors and pharmacies, with reimbursement mainly from Medicare and commercial insurers.
UroGen’s products compete mainly with surgical removal of tumors, and more broadly with bladder cancer therapies from companies such as Johnson & Johnson and CG Oncology. Its edge rests on its hydrogel delivery technology, approved non-surgical treatments for low-grade disease and a specialized sales force calling on urologists. Investors who follow URGN stock tend to watch ZUSDURI sales growth, the number of treating sites and prescribers and the rate of repeat use. JELMYTO sales are closely followed. Progress of UGN-103 toward approval, operating losses, cash use and patent protection are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward URGN’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
58Pulling it up
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Year-over-year revenue growth for each of the last four quarters, weighted toward the latest.
How the latest quarter's revenue compares with the average of the last four, plus a bonus for steady quarterly revenue.
Holding it back
Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.
5-year earnings growth evaluates long-term profit trajectory and consistency.
Return on Assets (ROA) shows how efficiently a company uses its assets to generate profit.
35 weighted scorers; 4 had no data today and are left out rather than counted as zero.
Technical · daily
44Pulling it up
Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.
- VWAP100
Volume Weighted Average Price (VWAP) shows the average price weighted by volume.
- ADX (14)100
ADX (14) measures how strong a trend is, and the DI lines give its direction: a strong uptrend scores high and a strong downtrend scores low.
Holding it back
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
Simple Moving Average (100-period) provides a longer-term perspective on price trends.
Where the close sits against its 100-day SMA.
61 weighted scorers; 4 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 53
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 64 | 1 |
| Daily | 44 | 3 |
| Weekly | 54 | 2 |
| Monthly | 64 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 58 |
| Nov 18, 2026 | 56 |
| Nov 17, 2026 | 56 |
| Nov 16, 2026 | 56 |
| Nov 15, 2026 | 55 |
| Nov 14, 2026 | 55 |
| Nov 13, 2026 | 56 |
| Nov 12, 2026 | 56 |
| Nov 11, 2026 | 46 |
| Nov 10, 2026 | 45 |
| Nov 8, 2026 | 44 |
| Nov 7, 2026 | 44 |
| Nov 6, 2026 | 44 |
| Nov 5, 2026 | 45 |
| Nov 4, 2026 | 47 |
| Nov 3, 2026 | 53 |
| Nov 2, 2026 | 53 |
| Nov 1, 2026 | 49 |
| Oct 30, 2026 | 49 |
| Oct 29, 2026 | 49 |
| Oct 28, 2026 | 51 |
| Oct 27, 2026 | 50 |
| Oct 26, 2026 | 50 |
| Oct 25, 2026 | 50 |
| Oct 24, 2026 | 50 |
| Oct 23, 2026 | 50 |
| Oct 22, 2026 | 51 |
| Oct 21, 2026 | 51 |
| Oct 20, 2026 | 51 |
| Oct 19, 2026 | 50 |
| Oct 18, 2026 | 50 |
| Oct 17, 2026 | 50 |
| Oct 16, 2026 | 50 |
| Oct 15, 2026 | 51 |
| Oct 14, 2026 | 50 |
| Oct 13, 2026 | 52 |
| Oct 12, 2026 | 52 |
| Oct 11, 2026 | 51 |
| Oct 10, 2026 | 51 |
| Oct 9, 2026 | 51 |
| Oct 8, 2026 | 51 |
| Oct 7, 2026 | 53 |
| Oct 6, 2026 | 55 |
| Oct 5, 2026 | 56 |
| Oct 4, 2026 | 55 |
| Oct 3, 2026 | 55 |
| Oct 2, 2026 | 55 |
| Oct 1, 2026 | 53 |
| Sep 30, 2026 | 53 |
| Sep 29, 2026 | 53 |
| Sep 28, 2026 | 53 |
| Sep 27, 2026 | 54 |
| Sep 26, 2026 | 54 |
| Sep 25, 2026 | 53 |
| Sep 24, 2026 | 54 |
| Sep 23, 2026 | 55 |
| Sep 22, 2026 | 54 |
| Sep 21, 2026 | 54 |
| Sep 20, 2026 | 55 |
| Sep 19, 2026 | 55 |
| Sep 18, 2026 | 55 |
| Sep 17, 2026 | 56 |
| Sep 16, 2026 | 55 |
| Sep 15, 2026 | 53 |
| Sep 14, 2026 | 54 |
| Sep 13, 2026 | 54 |
| Sep 12, 2026 | 54 |
| Sep 11, 2026 | 54 |
| Sep 10, 2026 | 53 |
| Sep 9, 2026 | 56 |
| Sep 8, 2026 | 56 |
| Sep 7, 2026 | 56 |
| Sep 6, 2026 | 56 |
| Sep 5, 2026 | 56 |
| Sep 4, 2026 | 56 |
| Sep 3, 2026 | 57 |
| Sep 2, 2026 | 57 |
| Sep 1, 2026 | 57 |
| Aug 31, 2026 | 55 |
| Aug 30, 2026 | 55 |
| Aug 29, 2026 | 55 |
| Aug 28, 2026 | 55 |
| Aug 27, 2026 | 55 |
| Aug 26, 2026 | 57 |
| Aug 25, 2026 | 56 |
| Aug 24, 2026 | 56 |
| Aug 23, 2026 | 57 |
| Aug 22, 2026 | 57 |
Key facts
- Market cap
- $1.6B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 1.64
- Risk grade (1–10)
- 2
- Next earnings
- Nov 4, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| RXRX Recursion Pharmaceuticals | $1.7B | 45 |
| VIR Vir Biotechnology | $1.7B | 54 |
| SRPT Sarepta Therapeutics | $1.5B | 41 |
| PGEN Precigen | $1.5B | 52 |
| NRIX Nurix Therapeutics | $1.5B | 56 |
| MESO Mesoblast | $1.5B | 49 |
Questions
What is URGN's stock rating today?
URGN scores 58/100 (Neutral) as of Nov 19, 2026: technical 54, fundamental 58, and news sentiment 53, which is shown but not counted. Scores are recomputed every night.
What does UroGen Pharma do?
UroGen Pharma (URGN) is a biotechnology company focused on treatments for urothelial and other specialty cancers. Its products use a proprietary reverse-thermal hydrogel that is liquid when cold and turns into a gel at body temperature, letting the chemotherapy drug mitomycin stay in contact with tumors longer than a standard liquid would.
Is URGN stock a buy?
The score is not a buy or sell recommendation. A 58 says the technical and fundamental signals we measure lean neutral today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the URGN score calculated?
96 weighted scorers feed it today: 35 fundamental, scored against Healthcare ranges, and 61 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/urgn/"><img src="https://stocksscores.com/stocks/urgn/badge.svg" alt="URGN stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/urgn/)